Manufacturers Life Insurance Company, The Selecta Biosciences Inc Transaction History

Manufacturers Life Insurance Company, The

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$1.02 - $1.23 $22,510 - $27,144	22,069 New	22,069 $23,000
Q2 2022 Aug 15, 2022	SELL	$0.67 - $1.4 $28,960 - $60,513	-43,224 Closed	0 $0
Q1 2022 Aug 11, 2023	BUY	$1.23 - $3.31 $53,165 - $143,071	43,224 New	43,224 $53,000
Q1 2022 May 20, 2022	SELL	$1.23 - $3.31 $10,077 - $27,118	-8,193 Reduced 15.93%	43,224 $53,000
Q4 2021 Feb 16, 2022	BUY	$2.89 - $4.43 $3,806 - $5,834	1,317 Added 2.63%	51,417 $168,000
Q3 2021 Nov 12, 2021	SELL	$3.36 - $4.62 $11,269 - $15,495	-3,354 Reduced 6.27%	50,100 $208,000
Q2 2021 Aug 12, 2021	BUY	$2.82 - $5.01 $31,349 - $55,696	11,117 Added 26.26%	53,454 $223,000
Q1 2021 May 03, 2021	SELL	$2.92 - $5.07 $8,634 - $14,991	-2,957 Reduced 6.53%	42,337 $192,000
Q4 2020 Feb 12, 2021	BUY	$1.64 - $3.42 $3,307 - $6,898	2,017 Added 4.66%	45,294 $137,000
Q2 2020 Aug 10, 2020	BUY	$1.83 - $4.06 $79,196 - $175,704	43,277 New	43,277 $122,000
Q2 2019 Aug 14, 2019	SELL	$1.79 - $3.05 $20,873 - $35,566	-11,661 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$1.47 - $3.06 $17,141 - $35,682	11,661 New	11,661 $28,000
Q3 2018 Nov 14, 2018	SELL	$12.07 - $16.0 $193,240 - $256,160	-16,010 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$9.36 - $13.25 $132,210 - $187,156	14,125 Added 749.34%	16,010 $213,000
Q1 2018 May 15, 2018	SELL	$8.49 - $11.82 $11,970 - $16,666	-1,410 Reduced 42.79%	1,885 $19,000
Q4 2017 Feb 08, 2018	SELL	$8.97 - $23.38 $78,514 - $204,645	-8,753 Reduced 72.65%	3,295 $33,000
Q3 2017 Nov 14, 2017	BUY	$15.22 - $20.03 $183,370 - $241,321	12,048	12,048 $219,000

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.